Navigation Links
CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference

Preclinical Studies of Valecor Platinum(TM) Coronary Stent System Indicate Positive Results and Improvements Compared to Market-Leading Bare Stent

BURLINGTON, Mass., Oct. 23 /PRNewswire/ -- CorNova, Inc. announced today that S. Eric Ryan, M.D., Chairman & CEO of CorNova, presented preliminary results of its recent preclinical studies for CorNova's Valecor Platinum(TM) Coronary Stent System at the TCT 2007 conference in Washington, D.C. The independently-conducted preclinical studies illustrated what CorNova believes to be meaningful improvements in neointimal proliferation, arterial injury, arterial inflammation, and reendothelialization when compared to a market-leading bare stent in rabbit and porcine models.

(Logo: )

Commenting on today's announcement, Dr. Ryan stated, "We are very pleased with the results from these preclinical studies of our Valecor Platinum(TM) Stent, which is designed to maximize biocompatibility while minimizing arterial injury, potentially providing both short and long-term benefits over current bare stent technology. We also believe our Valecor Platinum(TM) Stent may offer the potential of improving coronary stent performance without the need for drug-elution and the inherent risks presented by drug-eluting stents. The Company is proceeding with its efforts to receive CE Mark approval for the Valecor Platinum(TM) Stent and we currently expect to receive that approval in early 2008."

About CorNova

CorNova, Inc., founded in 2003, is a privately-held, development-stage company with an experienced international team of business, medical, and engineering professionals within the field of interventional cardiology. CorNova's business focus is to build value and opportunity through the utilization of the technologies, expertise, and resources of its international team and partner companies to develop and sell innovative endovascular devices. The Company's strategic partners include Implant Sciences Corporation (Amex: IMX) and CardioTech International, Inc. (Amex: CTE).

SOURCE CorNova, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Wound Care Market by Type (Dressings, Therapy Devices, Active ... Facility, Out-Patient Facility), and Geography - Global Forecast to ... --> --> The purpose of ... forecast of the global advanced wound care market. It ...
(Date:11/26/2015)... 26, 2015 ... adds "Global Repaglinide Industry 2015 ... on China Repaglinide Market, 2010-2019" reports ... and information to its online business ... . --> ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... ... Beginning November 30th at 6:00 a.m. EST until 11:59 p.m. EST, customers ... up to 20% off orders $80 or more to free gifts with purchases, there will ... As a competitive e-commerce website for skin care and cosmetic needs, customers will save on ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... According to ... are not changing the way that they are handling security in light of the ... and security presence in an attempt to stop an attack from reaching U.S. soil. ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Lizzie’s Lice Pickers ... company is offering customers 10% off of their purchase of lice treatment product. In ... full price. According to a company spokesperson. “Finding lice is a sure way to ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
Breaking Medicine News(10 mins):